Neurofibromatosis Type 1

Slide 1 · Neurofibromatosis Type 1

Genetics • Tumor biology • Neurofibroma morphology • Malignant progression

Dr Abu Suraih Sakhri

MBBS, MD (Pathology)

www.abusuraihsakhri.com

Slide 2 · Learning objectives

Relate NF1 tumor-suppressor loss to sustained RAS signaling.

Distinguish cutaneous, diffuse, and plexiform neurofibroma morphologies.

Explain neoplastic Schwann cells and stromal cooperation.

Connect multisystem phenotype to the risk of malignant nerve-sheath tumors.

Slide 3 · Peripheral nerve sheath tumors: The framework

Schwannoma

Schwann-cell tumor; Prominently associated with NF2.

Neurofibroma

Heterogeneous tumor; Sporadic or NF1-associated.

MPNST

Malignant peripheral nerve sheath tumor; May arise in NF1.

Slide 4 · NF1 belongs to a family of tumor syndromes

NF1, NF2, and schwannomatosis are distinct familial tumor syndromes.

Shared peripheral nerve associations do not imply identical tumor spectra.

NF1 particularly links neurofibroma formation with MPNST risk.

Inherited susceptibility

Characteristic nerve-associated tumors

Distinct clinicopathologic syndromes

Schematic (editable; Not a tissue image)

Slide 5 · NF1 is a multisystem neoplastic disorder

NF1 combines nonneoplastic manifestations with multiple tumor types.

The disease affects the skin, nerves, eye, skeleton, and nervous system.

Its manifestations cannot be explained by a single localized mass.

Cutaneous

Macules; Neurofibromas

Neural

Nerve sheath tumors; Gliomas

Ocular

Lisch nodules; Optic glioma

Other

Skeletal defects; Pheochromocytoma

Slide 6 · NF1 is relatively common

A frequency of approximately 1 in 3,000 individuals.

Its clinical importance extends beyond the presence of cutaneous tumors.

The associated neoplastic spectrum includes benign and malignant entities.

~1 / 3,000

Reported frequency of NF1

Slide 7 · Autosomal dominant inheritance

The disorder follows an autosomal dominant pattern.

One inherited pathogenic NF1 allele is sufficient for constitutional susceptibility.

Development of a given tumor is linked to further loss of NF1 function in neoplastic cells.

Constitutional NF1 variant

Second inactivating event

Biallelic NF1 loss in neoplastic Schwann cells

Schematic (editable; Not a tissue image)

Slide 8 · High penetrance is not uniform severity

NF1 is characterized by high penetrance.

Clinical expression varies widely across affected individuals.

Severity must not be inferred solely from the inheritance pattern.

Pathogenic NF1 variant

High likelihood of a phenotype

Widely differing manifestations

Schematic (editable; Not a tissue image)

Slide 9 · Variable expressivity explains clinical diversity

Some affected individuals have relatively subtle cutaneous findings.

Others develop numerous tumors and serious systemic manifestations.

Phenotypic variability occurs within the same genetic disease.

Mild

Subtle pigmentation

Intermediate

Multiple neurofibromas

Severe

Extensive multi-organ disease

Schematic (editable; Not a tissue image)

Slide 10 · Mosaic NF1 can produce regional disease

Some patients have manifestations limited to specific body regions.

Such localized patterns to mosaicism.

The clinical distribution reflects which cell populations harbor the alteration.

Early developmental NF1 change

Only a subset of cell lineages harbors the variant

Regionally distributed phenotype

Schematic (editable; Not a tissue image)

Slide 11 · Large NF1 deletions may confer severe phenotypes

Large chromosomal deletions can extend beyond the NF1 locus.

Loss of adjacent genes is associated with more severe manifestations.

Variant architecture therefore contributes to phenotypic severity.

NF1-spanning deletion

Involvement of adjacent genes

Tendency toward more severe disease

Schematic (editable; Not a tissue image)

Slide 12 · The NF1 locus is on chromosome 17

NF1 resides at 17q11.2.

It encodes the protein neurofibromin.

Its loss-of-function status establishes NF1 as a tumor-suppressor syndrome.

Chromosome 17

NF1 at 17q11.2

Gene product: Neurofibromin

Schematic (editable; Not a tissue image)

Slide 13 · Neurofibromin is the NF1 gene product

Neurofibromin is a negative regulator of RAS signaling.

Normal neurofibromin limits activation of a growth-promoting signaling switch.

Its absence is central to NF1-associated neoplasia.

NF1 gene

Neurofibromin protein

Restraint of active RAS

Schematic (editable; Not a tissue image)

Slide 14 · NF1 functions as a tumor suppressor

Inherited loss of one NF1 copy predisposes tissues to tumor formation.

NF1-related neoplastic cells have biallelic defects.

The decisive tumor-cell effect is complete loss of neurofibromin.

Constitutional NF1 variant

Second inactivating event

Biallelic NF1 loss in neoplastic Schwann cells

Schematic (editable; Not a tissue image)

Slide 15 · RAS signaling has active and inactive states

RAS switches between GTP-bound active and GDP-bound inactive forms.

Neurofibromin accelerates RAS GTP hydrolysis and limits signaling.

The relevant pathology is failure to terminate RAS activity.

RAS–GTP

RAS–GDP

Neurofibromin promotes GTP hydrolysis

Activation cycle

Schematic (editable; Not a tissue image)

Slide 16 · Neurofibromin loss prolongs RAS activity

With NF1 loss, RAS remains in its active state for longer.

Prolonged signaling can promote cell growth and survival.

This provides the molecular link from tumor-suppressor loss to tumor formation.

Loss of neurofibromin

Failure to restrain active RAS

Growth-promoting signaling

Schematic (editable; Not a tissue image)

Slide 17 · An inherited variant creates susceptibility

Constitutional NF1 loss of function affects multiple cell lineages.

Syndromic findings can occur without a tumor at every anatomic site.

Tumor development requires a separate explanation at the cellular level.

Constitutional heterozygosity

Systemic predisposition

Localized neoplastic outgrowth

Schematic (editable; Not a tissue image)

Slide 18 · Biallelic NF1 defects occur in tumor cells

Biallelic NF1 defects in NF1-related neoplastic cells.

Both copies of the tumor-suppressor gene lose effective function.

This explains why a focal tumor can arise in a systemic disorder.

Constitutional NF1 variant

Second inactivating event

Biallelic NF1 loss in neoplastic Schwann cells

Schematic (editable; Not a tissue image)

Slide 19 · The neoplastic population is not the entire lesion

Neurofibromas contain several cellular populations.

Complete loss of neurofibromin identifies the neoplastic Schwann cells.

Other intermixed populations participate in the tumor environment.

Neoplastic Schwann cell

Associated stromal cell

Schematic (editable; Not a tissue image)

Slide 20 · Schwann cells are the neoplastic component

Neurofibroma Schwann cells show complete neurofibromin loss.

They are admixed with stromal and inflammatory cells.

Morphologic heterogeneity does not imply that every cell is neoplastic.

Neoplastic Schwann cell

Associated stromal cell

Schematic (editable; Not a tissue image)

Slide 21 · The neurofibroma microenvironment is mixed

Neurofibromas include perineurial-like cells, fibroblasts, and mast cells.

CD34-positive spindle cells are another stromal population.

Neoplastic Schwann cells and associated cells form a cellular ecosystem.

Neoplastic Schwann cell

Associated stromal cell

Schematic (editable; Not a tissue image)

Slide 22 · Haploinsufficiency modifies the stroma

Feature

Schwann cells

Associated stromal cells

NF1 status

Biallelic loss

Often NF1 haploinsufficient

Neoplastic role

Tumor-forming population

Supportive tumor microenvironment

Mechanistic implication

Autonomous RAS dysregulation

Altered response to local signals

Slide 23 · Mast cells contribute to reciprocal signaling

NF1-haploinsufficient mast cells may be hypersensitive to KIT ligand.

Schwann cells can provide the KIT ligand.

Activated mast cells may secrete factors that stimulate Schwann-cell growth.

Schwann-cell KIT ligand

Hypersensitive mast-cell response

Growth-supporting factors

Schematic (editable; Not a tissue image)

Slide 24 · Tumor–stroma cross-talk is mechanistically important

Tumor growth reflects reciprocal signals, not merely Schwann-cell proliferation.

The mast-cell/KIT example illustrates paracrine support.

KIT signaling as a potential therapeutic target, not as established curative therapy.

Neoplastic Schwann cell

KIT-responsive mast cell

Feedback supporting growth

Schematic (editable; Not a tissue image)

Slide 25 · Different neurofibromas may have distinct origins

Plexiform and dermal neurofibromas may arise from distinct precursors.

These proposed precursors are neural crest–derived.

Different progenitors help explain divergent growth patterns.

Neural crest lineage

Distinct precursor populations

Distinct neurofibroma patterns

Schematic (editable; Not a tissue image)

Slide 26 · NF1-associated tumors extend beyond nerves

Neurofibromas, MPNSTs, optic nerve gliomas, other gliomas, and pheochromocytomas.

The spectrum includes lesions of differing tissue origin and behavior.

Clinical evaluation should not equate NF1 solely with cutaneous neurofibromas.

Cutaneous

Macules; Neurofibromas

Neural

Nerve sheath tumors; Gliomas

Ocular

Lisch nodules; Optic glioma

Other

Skeletal defects; Pheochromocytoma

Slide 27 · Optic nerve gliomas are part of the NF1 spectrum

Optic nerve glioma is a characteristic associated tumor.

It illustrates involvement of the central nervous system.

Its inclusion is a tumor-spectrum association, not a histologic diagnosis from skin findings.

NF1 susceptibility

Optic nerve glial neoplasm

Neuro-ophthalmic tumor association

Schematic (editable; Not a tissue image)

Slide 28 · Other gliomas also occur in NF1

The associated glioma spectrum is not confined to the optic nerve.

The Robbins peripheral nerve chapter cross-references the CNS chapter.

Histologic classification of specific gliomas is outside this NF1 unit.

Constitutional NF1 defect

Central nervous system tumor susceptibility

Gliomas beyond the optic nerve

Schematic (editable; Not a tissue image)

Slide 29 · Pheochromocytoma represents a distinct tumor lineage

Pheochromocytomas are included among NF1-associated neoplasms.

They show that the disease predisposes to tumors beyond nerve sheaths.

Do not mistake a pheochromocytoma for a neurofibroma morphologically.

NF1 tumor predisposition

Adrenal medullary neoplasm

Pheochromocytoma

Schematic (editable; Not a tissue image)

Slide 30 · Café-au-lait spots are nonneoplastic signs

Feature

Café-au-lait macule

Neurofibroma

Category

Pigmented macule

Benign nerve sheath tumor

Pathologic process

Hyperpigmentation

Schwann-cell neoplasia with stroma

Role in NF1

Nonneoplastic manifestation

Associated tumor phenotype

Slide 31 · Lisch nodules are ocular findings

Feature

Lisch nodule

Optic nerve glioma

Location

Iris

Optic nerve

Category

Pigmented ocular nodule

Glial tumor

Teaching point

Clinical phenotype

Neoplastic association

Slide 32 · Skeletal defects belong to the NF1 phenotype

Skeletal abnormalities are included among the nonneoplastic manifestations.

They reinforce the systemic nature of the disease.

A tumor-only conceptual model misses an important category of findings.

Cutaneous

Macules; Neurofibromas

Neural

Nerve sheath tumors; Gliomas

Ocular

Lisch nodules; Optic glioma

Other

Skeletal defects; Pheochromocytoma

Slide 33 · Neurologic manifestations are not all tumors

Feature

Nonneoplastic features

Neoplastic features

Examples

Intellectual disability; Seizures

Gliomas; Neurofibromas

Category

Clinical manifestations

Tumor lesions

Interpretation

Systemic disease effects

Tumor-type evaluation

Slide 34 · The NF1 phenotype integrates several organ systems

Skin findings can coexist with ocular, skeletal, and nervous-system changes.

Associated tumors may involve peripheral nerves, CNS, or adrenal tissue.

The breadth of findings reflects multisystem constitutional susceptibility.

Cutaneous

Macules; Neurofibromas

Neural

Nerve sheath tumors; Gliomas

Ocular

Lisch nodules; Optic glioma

Other

Skeletal defects; Pheochromocytoma

Slide 35 · Neurofibromas can be sporadic or syndromic

Feature

Sporadic neurofibroma

NF1-associated neurofibroma

Presentation

May be isolated

May be multiple or plexiform

Genetic context

No inferred systemic NF1 diagnosis

Constitutional NF1 susceptibility

Caution

Single lesion ≠ syndrome

Integrate systemic findings

Slide 36 · Neurofibromas have heterogeneous cellularity

The neoplastic component shows Schwann-cell differentiation.

Additional cells include fibroblasts, perineurial-like cells, mast cells, and CD34-positive spindle cells.

This heterogeneity helps separate neurofibroma from a purely Schwann-cell tumor model.

Neoplastic Schwann cell

Associated stromal cell

Schematic (editable; Not a tissue image)

Slide 37 · Three neurofibroma growth patterns

Localized cutaneous

Small dermal/subcutaneous, often pedunculated nodules.

Diffuse

Broad infiltrative plaque involving skin or soft tissue.

Plexiform

Multifascicular nerve-associated growth; Characteristically NF1.

Slide 38 · Cutaneous neurofibroma: Clinical growth pattern

Superficial cutaneous neurofibromas often appear as pedunculated nodules.

They may occur singly in sporadic disease.

Multiple cutaneous neurofibromas may accompany NF1.

Schematic (editable; Not a tissue image)

Slide 39 · Localized neurofibroma is well delimited but unencapsulated

Localized lesions arise in dermis and subcutaneous fat.

They are relatively well circumscribed without a complete capsule.

Histology typically shows low cellularity and a bland spindle-cell component.

Schematic (editable; Not a tissue image)

Slide 40 · The matrix of localized neurofibroma is loose

The supporting stroma includes loose collagen.

Schwann cells intermingle with other stromal elements.

Bland cytology and low cellularity should be interpreted with the growth pattern.

Neoplastic Schwann cell

Associated stromal cell

Schematic (editable; Not a tissue image)

Slide 41 · Adnexal structures can be trapped at lesion edges

Localized cutaneous neurofibromas may entrap adnexal structures.

This does not automatically indicate malignant invasion.

The lesion remains a benign, often unencapsulated proliferation.

Schematic (editable; Not a tissue image)

Slide 42 · Diffuse neurofibroma has an infiltrative growth pattern

Diffuse neurofibroma extends through dermis, subcutis, or deeper soft tissues.

The lesion forms a large, frequently plaque-like elevation.

Growth pattern—not cytologic atypia—distinguishes it from localized neurofibroma.

Schematic (editable; Not a tissue image)

Slide 43 · Diffuse neurofibroma entraps normal tissues

The tumor may permeate fat and entrap skin appendages.

Entrapment is an architectural clue to diffuse extension.

Cytology may remain similar to localized neurofibroma.

Schematic (editable; Not a tissue image)

Slide 44 · Pseudo-Meissner corpuscles can occur in diffuse lesions

Focal cell clusters may resemble tactile corpuscles.

These are termed pseudo-Meissner corpuscles or tactile-like bodies.

They are an associated morphologic feature, not a separate neoplasm.

Diffuse neurofibroma

Focal tactile-like cellular structures

Pseudo-Meissner corpuscles

Schematic (editable; Not a tissue image)

Slide 45 · Plexiform neurofibroma involves multiple fascicles

Plexiform lesions expand several nerve fascicles.

They may arise in superficial or deep nerves, including roots and larger nerves.

Their multifascicular architecture is a defining diagnostic concept.

Schematic (editable; Not a tissue image)

Slide 46 · Plexiform growth remodels nerve anatomy

Tumor cells expand fascicles within the nerve.

Associated axons are entrapped in the expanded structures.

The architecture is distinct from a tumor merely pushing a nerve aside.

Schematic (editable; Not a tissue image)

Slide 47 · The outer perineurium may be preserved

The external perineurial layer remains around expanded fascicles.

Individual fascicles may therefore appear encapsulated.

An apparent fascicular boundary does not mean the entire plexiform lesion is encapsulated.

Schematic (editable; Not a tissue image)

Slide 48 · Entrapped axons are an important architectural clue

Plexiform neurofibromas incorporate existing nerve fascicles.

Axons can remain entrapped amid the proliferating cells.

Understanding this feature clarifies their relationship to the parent nerve.

Schematic (editable; Not a tissue image)

Slide 49 · Plexiform neurofibroma: “bag of worms” pattern

Multiple enlarged, tortuous fascicles produce a ropy gross configuration.

The gross appearance as a “bag of worms.”

The term reflects the multifascicular growth pattern rather than a separate histologic subtype.

Schematic (editable; Not a tissue image)

Slide 50 · Plexiform lesions show variable extracellular matrix

The stroma ranges from loose and myxoid to collagenous and fibrous.

Neurofibroma cells remain mixed with nonneoplastic stromal populations.

Matrix heterogeneity is compatible with the same neurofibroma category.

Neoplastic Schwann cell

Associated stromal cell

Schematic (editable; Not a tissue image)

Slide 51 · “Shredded carrot” collagen is a morphologic metaphor

Plexiform neurofibromas may contain slender, wavy collagen bundles.

Robbins likens this collagen to shredded carrots.

The descriptor refers to collagen morphology; It is not a stain or molecular test.

Wavy collagen bundles (conceptual)

Schematic (editable; Not a tissue image)

Slide 52 · Plexiform neurofibromas are strongly tied to NF1

Feature

Localized cutaneous

Plexiform

Anatomic pattern

Small skin nodule

Several enlarged nerve fascicles

Syndromic implication

May be sporadic

Strong NF1 association

Growth

Dermal/subcutaneous

Nerve-related, multifascicular

Slide 53 · Growth pattern distinguishes neurofibroma variants

Localized

Nodular architecture; Well delimited but unencapsulated.

Diffuse

Broad tissue infiltration; Trapped fat and appendages.

Plexiform

Many swollen nerve fascicles; Axons remain entrapped.

Slide 54 · Neurofibroma and schwannoma are not interchangeable

Feature

Neurofibroma

Schwannoma

Cell composition

Mixed stromal cell population

Predominantly Schwann cells

Nerve relationship

May incorporate nerve fascicles/axons

Typically displaces adjacent nerve

Syndromic association

NF1 (especially plexiform)

NF2 (especially vestibular)

Slide 55 · Tumor architecture can predict surgical difficulty

Feature

Schwannoma

Plexiform neurofibroma

Pattern

Expansile mass adjacent to nerve

Enlargement of many fascicles

Axons

Parent nerve commonly displaced

Associated axons entrapped

Implication

Separable plane may exist

Integrated nerve anatomy complicates separation

Slide 56 · Neurofibroma may progress to MPNST

In NF1, MPNSTs can arise through transformation of preexisting neurofibromas.

This benign-to-malignant progression is unusual among soft tissue tumors.

Plexiform neurofibromas are the usual precursor.

NF1-associated plexiform neurofibroma

Accumulation of malignant change

Malignant peripheral nerve sheath tumor

Schematic (editable; Not a tissue image)

Slide 57 · MPNST risk is a clinically important NF1 consequence

An overall NF1-associated MPNST incidence of approximately 5%–10%.

The stated figure concerns NF1 patients, not all neurofibromas.

Benign morphology at one site does not negate the long-term systemic tumor risk.

5%–10%

Reported overall incidence of MPNST among patients with NF1

Slide 58 · MPNST risk is not equally distributed

Large numbers of plexiform neurofibromas are associated with greater risk.

Large NF1 deletions are also associated with increased risk.

These modifiers should not be converted into individual numerical forecasts.

NF1 patient population

Extensive plexiform burden or large deletion

Higher MPNST risk subgroup

Schematic (editable; Not a tissue image)

Slide 59 · MPNST is a distinct malignant tumor category

Feature

Benign neurofibroma

MPNST

Biologic category

Benign peripheral nerve sheath tumor

Malignant peripheral nerve sheath tumor

Typical pattern

Bland mixed spindle-cell lesion

Frequently high-grade malignancy

Relation to NF1

Common association

Major malignant complication

Slide 60 · NF1 and NF2 differ in their hallmark tumors

Feature

NF1

NF2

Gene

NF1; Neurofibromin; 17q11.2

NF2; Merlin; 22q12

Nerve tumor

Neurofibroma (especially plexiform)

Vestibular schwannoma

Other tumors

MPNST; Optic glioma; Pheochromocytoma

Meningioma; Spinal ependymoma

Inheritance

Autosomal dominant

Autosomal dominant

Slide 61 · Histologic categories must be inferred cautiously

Morphologic clues establish a pattern but do not substitute for complete clinicopathologic correlation.

A single sporadic neurofibroma does not establish NF1.

A multifascicular plexiform lesion warrants particular attention to syndromic context.

Assess lesion architecture

Identify neurofibroma growth pattern

Integrate multisystem NF1 findings

Schematic (editable; Not a tissue image)

Slide 62 · Case: A child with skin findings and nerve enlargement

Case vignette

A child has several café-au-lait macules and an enlarging, rope-like mass tracking along a peripheral nerve.

What two categories of findings are present?

Interpretation

Pigmentary finding: Nonneoplastic macules. Nerve mass: Morphologically suggestive of a plexiform neurofibroma. Together, they support consideration of NF1.

Slide 63 · Case: Why is only one cell population neoplastic?

Case vignette

A neurofibroma contains Schwann cells, mast cells, fibroblasts, and perineurial-like cells. Genetic assessment finds complete NF1 loss only in the Schwann cells.

Which population is neoplastic, and why?

Interpretation

The Schwann cells are the neoplastic population. Other associated cells can influence growth without the same biallelic NF1 loss.

Slide 64 · Case: Distinguish a diffuse lesion from plexiform growth

Case vignette

Two benign spindle-cell lesions are reviewed. One permeates dermis and adipose tissue; The other expands several discrete nerve fascicles and traps axons.

What growth-pattern labels fit these lesions?

Interpretation

First: Diffuse neurofibroma. Second: Plexiform neurofibroma. Architecture matters more than generic spindle-cell appearance.

Slide 65 · Case: Interpret the inherited and somatic defects

Case vignette

A patient has an inherited NF1 loss-of-function variant; An associated neurofibroma shows biallelic inactivation in its Schwann-cell component.

Why are the systemic phenotype and focal tumor different?

Interpretation

Constitutional heterozygosity produces susceptibility; A further localized defect produces complete tumor-suppressor loss in neoplastic cells.

Slide 66 · NF1 connects genotype, stroma, and morphology

Genotype: Inherited NF1 loss of function and biallelic tumor-cell loss.

Mechanism: Defective RAS restraint with stromal support.

Morphology: Heterogeneous neurofibromas whose architecture varies by growth pattern.

NF1 genetic predisposition

RAS dysregulation + microenvironment

Distinct neurofibroma phenotypes

Schematic (editable; Not a tissue image)

Slide 67 · Integrating the tumor spectrum with systemic signs

Benign nerve tumors coexist with pigmentary, ocular, skeletal, and neurologic features.

Associated gliomas and pheochromocytomas broaden the neoplastic spectrum.

MPNST is the central malignant nerve-sheath complication.

Cutaneous

Macules; Neurofibromas

Neural

Nerve sheath tumors; Gliomas

Ocular

Lisch nodules; Optic glioma

Other

Skeletal defects; Pheochromocytoma

Slide 68 · Scope of pathology-based diagnostic reasoning

Robbins supports recognizing NF1 by its genotype, manifestations, and tumor spectrum.

This lecture does not substitute formal consensus diagnostic criteria.

The provided textbook excerpt does not enumerate criterion counts, age thresholds, or surveillance schedules.

Source-supported syndrome recognition

Clinicopathologic correlation

Separate verification of formal criteria

Schematic (editable; Not a tissue image)

Slide 69 · Mechanisms to retain

NF1 at 17q11.2 encodes neurofibromin, a RAS-negative regulator.

Neoplastic Schwann cells lose both NF1 alleles.

KIT-responsive mast cells illustrate tumor–microenvironment cooperation.

Plexiform neurofibromas are a major precursor setting for MPNST.

Loss of neurofibromin

Persistent RAS signaling

Schwann-cell tumor + stromal support

Potential malignant transformation

Schematic (editable; Not a tissue image)

Slide 70 · References and source scope

Robbins, Cotran & Kumar: Pathologic Basis of Disease. 11th edition (2026).

Chapter 27: Peripheral Nerves and Skeletal Muscles; NF1 and neurofibroma sections, pp. 1125–1127.

Clinical and genetic distinctions are restricted to the supplied Robbins text and adjacent chapter context.

Diagrams are original editable schematics; no synthetic image is presented as histologic evidence.